|
||
Erythromycin Community Pharm Pregnancy |
||
Erythromycin Community Pharm crosses the placenta in small amounts. In one study of 11 patients who had detectable Erythromycin Community Pharm levels in the serum, 4 infants did not have detectable cord concentrations. The cord concentrations in the remaining 7 infants generally ranged from 1% to 6% of that found in maternal serum. A case of left absence-of-tibia syndrome was reported in an infant whose mother had received Erythromycin Community Pharm, ethisterone, and ethinyl estradiol at approximately 4 weeks gestation. Erythromycin Community Pharm has been used prior to delivery in women colonized with group B beta-hemolytic streptococcus to reduce infant colonization. No adverse events in the infants have been reported. Erythromycin Community Pharm has also been used to treat genital Mycoplasma infection during the first trimester without evidence of fetal adverse effects. Pregnant women receiving Erythromycin Community Pharm estolate may be more prone to hepatotoxicity. In one study of women receiving Erythromycin Community Pharm estolate between the 22nd and 32nd week of pregnancy, 10% showed abnormal levels of SGOT.
Erythromycin Community Pharm has been assigned to pregnancy category B by the FDA. Animal studies failed to reveal evidence of teratogenicity. There are no controlled data in human pregnancy. The Centers for Disease Control and Prevention considers Erythromycin Community Pharm the drug of choice for treatment of Chlamydia infections in pregnant women. However, Erythromycin Community Pharm estolate is considered contraindicated because of drug-related hepatotoxicity. Erythromycin Community Pharm should only be given during pregnancy when need has been clearly established.
See references
Erythromycin Community Pharm is excreted into human milk in small amounts. Erythromycin Community Pharm is considered compatible with breast-feeding by the American Academy of Pediatrics.
See references
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|